FDA public meeting on CNPV pilot highlights split between industry praise and transparency concerns

The Food and Drug Administration convened a Part 15 public meeting to gather feedback on the Commissioner's National Priority Voucher (CNPV) Pilot Program, drawing industry praise for operational gains and pointed criticism over transparency, selection criteria, and potential safety tradeoffs.

At the opening, FDA officials described CNPV as an ‘ultra‑accelerated’ review structure built on prior efforts such as Real‑Time Oncology Review, with presubmission engagement intended to shorten review timelines while preserving primary review teams’ decision-making authority. FDA officials asked stakeholders for input on eligible applications, the Review Council composition, selection timing, sponsor responsibilities, and evaluation metrics.

Industry sponsors said the program can deliver faster patient access when implemented with clear expectations and resourcing. "Collaboration included the review division, Commissioner's Office, and J&J to achieve efficient and expeditious review," said Ginny Beakes‑Read of Johnson & Johnson, who described the TECH‑3 application’s participation in the pilot and urged clearer communication channels and decision milestones. Merck’s regulatory lead, Ashley Wivel, recommended early, structured scientific engagement—especially for CMC and inspection readiness—to sustain review quality under an accelerated cadence.

Trade groups also urged predictability. "If FDA intends to extend the program beyond the pilot phase, PhRMA encourages rulemaking that establishes clear eligibility criteria, selection processes, operational expectations, and timelines," said Kelly Falconer Goldberg of PhRMA.

Patients, caregivers, and clinicians emphasized urgency for specific conditions and sought meaningful patient input. Christina DeGryse, speaking for the Huntington's disease community, asked FDA to treat irreversible neurodegenerative diseases as national priorities and to include disease‑specific clinical and statistical expertise on the Review Council. Several speakers underscored the human toll of delayed therapies and urged the agency to measure the program’s success by whether it meaningfully shortens time to effective treatments.

Public‑interest organizations and physician groups pressed for formal guardrails. "We urge reconsideration of the stated national priority criteria," said Janet Krommes of Doctors for America, citing concerns that vagueness could fuel perceptions of political influence and reduce trust. Peter Lurie of the Center for Science in the Public Interest warned that including non‑regulatory goals (such as pricing or domestic manufacturing) in selection considerations risks politicization and recommended winding down the program or formalizing clearer eligibility and review procedures.

Speakers raised operational and safety tradeoffs: some commenters noted that more rapid reviews can be associated with a higher chance of post‑market safety label changes and that staffing constraints could shift attention from other review priorities. Legal and procedural experts recommended issuing guidance or rulemaking to make the selection process defensible against administrative‑law challenges.

FDA closed the meeting by reminding stakeholders that the public docket remains open for written comments through June 29 and that the agency will consider input on selection criteria, Council composition, presubmission expectations, and evaluation metrics.

The meeting provided a cross‑section of perspectives: sponsors and developers described operational benefits and concrete suggestions for clearer milestones; patient advocates asked for formal mechanisms to ensure patient voices and disease‑specific expertise; independent groups urged transparency and procedural durability to preserve scientific integrity. The agency did not announce changes at the meeting; the docket remains open for further submissions.